Trading Signals: VBIV Stock Price Prediction and Forecast (Thu. May. 4, 2006 - Fri. Jul. 24, 2020)(VBI Vaccines Inc)
| VBIV latest price $26.6200 (19.69%) ($22.4200 - $26.6200) on Mon. Mar. 1, 2010. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.67% (three month average) | RSI | 79 | Latest Price | $26.6200(19.69%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | VBIV advances 4.3% a day on average for past five trading days. | Weekly Trend | VBIV advances 8.7% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support VBIV advance at 0% a week (0% probability) GLD(18%) OIH(12%) VWO(12%) EEM(11%) EWG(11%) | Factors Impacting VBIV price | VBIV will decline at least -3.335% in a week (0% probabilities). TLT(-6%) TIP(0%) SHY(1%) LQD(2%) XLU(4%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.335% (StdDev 6.67%) | Hourly BBV | 0 () | Intraday Trend | 18.7% | | | |
|
5 Day Moving Average | $23.25(14.49%) | 10 Day Moving Average | $22.02(20.89%) | 20 Day Moving Average | $20.51(29.79%) | To recent high | 0% | To recent low | 166.2% | Market Cap | $6.14b | | | | VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on July 9, 2015 is headquartered in Cambridge, MA.VBI's COVID-19 vaccine candidate, VBI-2901, is noteworthy because it could potentially also confer immunity to other coronaviruses which cause diseases like MERS (Middle Eastern Respiratory Syndrome). More importantly, VBI appears to be facing a bottleneck either in its preclinical research or its vaccine manufacturing capabilities. VBI doesn't expect to have the necessary clinical study materials assembled for its COVID-19 vaccine trial before the fourth quarter, meaning that it's roughly a quarter behind Vaxart in the development process. |